R&D Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic RegulationThis press release updates the IVDR Classification to Class B from the prior Class C. MINNEAPOLIS, Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regul ...

R&D Systems Hematology Controls and Calibrators has completed the Class C Certification under the new European Union In Vitro Diagnostic RegulationMINNEAPOLIS, Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regulations and guidelines set forth by the European Union for in-vitro diagnostic devices. ...

MINNEAPOLIS, Nov. 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:UBS Global Healthcare ConferenceNovember 12, 20249:30 AM PSTStifel 2024 Healthcare ConferenceNovember 19, 20248:00 AM ESTStephens NASH 2024 ConferenceNovember 20, 202411:00 AM CSTA live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.About Bio- ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference’s partnering meetings, Tiziana will engage with industry leaders, potenti ...

公司业务概况 - 公司业务分为生命科学和临床诊断两个报告分部[114] - 公司销售超过12,000种产品和服务,主要客户包括科研、医疗、教育和政府[115] 财务表现 - 2024年前三季度,公司总销售额为19亿美元,同比下降4.6%,其中生命科学分部销售下降15.1%,临床诊断分部销售增长4.1%[135][136][137] - 2024年第三季度,公司总销售额为6.497亿美元,同比增长2.8%,其中临床诊断分部销售增长5.6%[123][125] - 2024年前三季度,公司综合毛利率为54.6%,同比提高1.3个百分点,其中临床诊断分部毛利率提高2.2个百分点[138][140] - 2024年第三季度,公司研发费用占销售额14%,同比增加7.1个百分点,主要由于一次性并购研发费用[128][129] - 2024年前三季度,公司权益证券和贷款公允价值变动产生亏损16.8亿美元[145] - 2024年前三季度,公司税率为21.3%,同比下降1.5个百分点[147] 现金流情况 - 公司拥有1.63亿美元的现金、现金等价物和短期投资，其中约16%位于海外子公司[150] - 公司经营活动产生的现金流净额为3.31亿美元，较上年同期增加[152] - 公司投资活动使用的现金流净额为1.297亿美元，较上年同期增加[153] - 公司融资活动使用的现金流净额为1.926亿美元，较上年同期减少[154] 股票回购 - 公司在第三季度回购了33.0381万股A类普通股,总成本为9700万美元[156] - 公司董事会授权在2023年回购计划下再回购最多5亿美元的公司普通股[157] - 公司在第二季度回购了34.6226万股A类普通股,总成本为1亿美元[159] - 公司在第一季度回购了1.425万股A类普通股,总成本为470万美元[161] 股票发行 - 公司在第三季度发行了12.7328万股A类库存股以满足员工限制性股票和员工股票购买计划的授予[155] - 公司在第二季度发行了2.1017万股A类库存股以满足员工限制性股票和员工股票购买计划的授予[158]

Bio-Rad Laboratories, Inc. (BIO) posted third-quarter 2024 adjusted earnings per share (EPS) of $2.01, which beat the Zacks Consensus Estimate by 57%. However, the bottom line decreased 13.7% from the prior-year quarter’s level.The quarter’s adjustments primarily eliminate the impacts of certain non-recurring items, such as the amortization of purchased intangibles, restructuring costs and losses from the change in the fair market value of equity securities.The company’s GAAP EPS was $23.34, up 541.2% from ...

财务数据和关键指标变化 - 第三季度净销售额为6.5亿美元，较2023年第三季度的6.32亿美元增长2.8% [24] - 第三季度GAAP毛利率为54.8%，较2023年第三季度的53.1%有所提升 [30] - 第三季度净收入为6.53亿美元，稀释每股收益为23.34美元，较2023年第三季度的1.06亿美元和每股3.64美元显著增长 [34] - 非GAAP净收入为5600万美元，稀释每股收益为2.01美元，较2023年第三季度的6800万美元和每股2.33美元有所下降 [38] 各条业务线数据和关键指标变化 - 临床诊断部门的销售额为3.89亿美元，较2023年第三季度的3.68亿美元增长5.6% [27] - 生命科学部门的销售额约为2.61亿美元，与2023年第三季度的2.63亿美元基本持平 [25] - 生命科学部门在剔除过程色谱销售后，收入同比增长3.5% [26] 各个市场数据和关键指标变化 - 临床诊断部门在所有三个地区的货币中性收入均实现增长 [29] - 生命科学部门在美洲的货币中性销售下降，但在EMEA地区有所增长 [25] 公司战略和发展方向和行业竞争 - 公司致力于实现盈利性收入增长，目标是达到或超过市场增长率 [20] - 公司正在进行企业转型，专注于供应链和核心流程的改进，以支持更强的利润率 [15] - 公司在数字PCR平台上继续扩展应用，并通过合作伙伴关系推动增长 [16] 管理层对经营环境和未来前景的评论 - 管理层对生物科技和制药行业的需求恢复持谨慎态度，预计这种恢复将持续到2025年 [9] - 管理层指出，尽管客户对资金环境保持谨慎，但对数字PCR试剂和耗材的需求仍在增长 [12] 其他重要信息 - 公司在新加坡开设了一个新的亚洲配送中心，以提高物流效率 [15] - 公司完成了对Sabre Bio的收购，利用核心滴定技术发现新抗体和T细胞受体 [17] 问答环节所有提问和回答 问题: 关于毛利率的可持续性 - 管理层表示，毛利率的改善是可持续的，主要得益于产品组合和生产效率的提升 [47] 问题: 关于过程色谱的库存去化情况 - 管理层提到，客户的去库存仍在继续，预计这一过程将持续到2025年 [52] 问题: 关于Sartorius股份的变现意愿 - 管理层表示，尽管Sartorius的市场价值有所下降，但目前没有变现的必要 [54] 问题: 关于2025年的收入前景 - 管理层指出，2025年可能面临的挑战包括生物制药市场的疲软和中国市场的不确定性 [56] 问题: 关于数字PCR的定价策略 - 管理层承认市场竞争加剧，正在根据市场变化调整定价策略 [80]

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $2.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 57.03%. A quarter ago, it was expected that this maker of instruments used in biomedical research would post earnings of $2.12 per share when it actually produced earnings of $3.11, delivering a surprise of 46. ...

Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2024 Financial Results HERCULES, Calif.—October 30, 2024 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024. Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 percent compared to $632.1 million reported for the third quarter of 2023. On a currency-neutral basis, quarterl ...